Collin Tokheim
Research Fellows

Collin Tokheim

Postdoctoral Research Fellow

Biostatistics

ctokheim@hsph.harvard.edu


Overview

Collin Tokheim received his Ph.D. in Biomedical Engineering from Johns Hopkins University in 2018. During his Ph.D., his research focused on the development and application of novel computational methodologies to statistically implicate mutations underlying the development or progression of human cancers. He has expertise in machine learning, statistical modeling, genomics, and cancer genetics. Collin is now a Research Fellow at the Harvard School of Public Health and Dana-Farber Cancer Institute. Dr. Tokheim's current research focus is to understand how protein degradation is dysregulated in cancer and how this informs an emerging therapeutic paradigm of Targeted Protein Degradation (TPD) drugs. TPD drugs selectively and potently eliminate -- rather than inhibit -- disease causing proteins.

B.S., 04/2011, Biomedical Engineering
University of Iowa, Iowa City, IA

Ph.D., 12/2018, Biomedical Engineering
Johns Hopkins University, Baltimore, MD

Engineering Excellence Scholarship2007-2008
University of Iowa

E. Lester and Frances M. Williams Fund Scholarship2008-2009
University of Iowa

William C. Blackburn Engineering Scholarship2009-2011
University of Iowa

National Cancer Institute (NCI) NRSA Fellowship 2015-2018

Martin and Carol Macht Award
Johns Hopkins University

Damon Runyon Quantitative Biology Fellowship2020-Pres
Damon Runyon Cancer Research Foundation

Emerging Leaders in Computational Oncology Award
Memorial Sloan Kettering


Bibliography

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network.

Zeng Z, Fu J, Cibulskis C, Jhaveri A, Gumbs C, Das B, Sanchez-Espiridion B, Janssens S, Taing L, Wang J, Lindsay J, Vilimas T, Zhang J, Tokheim C, Sahu A, Jiang P, Yan C, Duose DY, Cerami E, Chen L, Cohen D, Chen Q, Enos R, Huang X, Lee JJ, Liu Y, Neuberg DS, Nguyen C, Patterson C, Sarkar S, Shukla S, Tang M, Tsuji J, Uduman M, Wang X, Weirather JL, Yu J, Yu J, Zhang J, Zhang J, Meerzaman D, Thurin M, Futreal A, Karlovich C, Gabriel SB, Wistuba II, Liu XS, Wu CJ.

Clin Cancer Res. 2021 09 15. 27(18):5049-5061. PMID: 33323402